2020
DOI: 10.1080/01902148.2020.1836691
|View full text |Cite
|
Sign up to set email alerts
|

Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 46 publications
0
2
0
Order By: Relevance
“…Nonetheless, considering the serious cardiovascular risks, heart failure, and hepatotoxicity associated with its use, PNT is generally limited to cases of second-generation drug-resistant leukemia and/or as third-line therapy in CML 4 6 . Recently, it was shown that PNT treatment resulted in a marked and dose-dependent increase in double-strand DNA break damage 7 .
Figure 1 Chemical structure of PNT.
…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Nonetheless, considering the serious cardiovascular risks, heart failure, and hepatotoxicity associated with its use, PNT is generally limited to cases of second-generation drug-resistant leukemia and/or as third-line therapy in CML 4 6 . Recently, it was shown that PNT treatment resulted in a marked and dose-dependent increase in double-strand DNA break damage 7 .
Figure 1 Chemical structure of PNT.
…”
Section: Introductionmentioning
confidence: 99%
“…Based on its effectiveness against chronic myeloid leukemia, ponatinib is undergoing intensive evaluation for its potential activity against other tumor types, such as liver cancer and malignant pleural mesothelioma 7 , 8 . From a chemical perspective several methods have been developed to date for the analytical determination of PNT and its main metabolite in plasma or urine 1 , 9 13 .…”
Section: Introductionmentioning
confidence: 99%